PFE Stock Risk & Deep Value Analysis
Pfizer Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About PFE Stock
We analyzed Pfizer Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PFE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
PFE Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new products fails to generate significant revenue (e.g., less than $3B annually from new launches in FY2026-2027) to offset these declines, it could lead to sustained revenue contraction and further pressure on adjusted EPS and cash flow generation beyond current guidance.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure post-COVID normalization.
- ⚠
High reliance on successful pipeline execution to offset significant revenue declines from mature products facing patent cliffs (e.g., Ibrance patent expiry in 2027, which generated billions annually).
- ⚠
Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale not seen by a traditional pharma company.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (August 4, 2026): A significant miss on adjusted EPS below $0.60 or failure to reaffirm full-year guidance could trigger a 5-10% stock decline.
- 📅
Loss of Exclusivity for Key Products (Ongoing through FY2027): Any accelerated or unexpected loss of exclusivity for major revenue drivers (e.g., Ibrance, Eliquis, Vyndaqel) beyond current projections, impacting $1B+ in annual revenue.
When to Reconsider
- 🚪
Exit if quarterly adjusted EPS consistently misses consensus estimates by more than 10% for two consecutive quarters.
- 🚪
Sell if FY2026 revenue guidance is downgraded below $59.5B or adjusted EPS guidance falls below $2.80.
- 🚪
Exit if a major late-stage pipeline asset (e.g., Phase 3 oncology drug) fails clinical trials or receives a Complete Response Letter from the FDA.
Unlock PFE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Pfizer Inc (PFE) Do?
Market Cap
$146.45B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
81,000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Visit Pfizer Inc WebsiteInvestment Thesis
If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward P/E multiple. This is bullish for income-focused investors, as the market currently undervalues its long-term stability and dividend yield, focusing heavily on post-COVID declines.
Is PFE Stock Undervalued?
Unlock the full AI analysis for PFE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PFE Price Targets & Strategy
12-Month Target
$30.45
Bull Case
$34.00
Bear Case
$24.00
Valuation Basis
Based on 10.5x forward P/E applied to midpoint of FY2026 adjusted EPS guidance ($2.90) = $30.45
Entry Strategy
Dollar-cost average between $25.00-$26.00, near recent support levels and current trading range. A dip towards $24.00 could be a stronger entry point.
Exit Strategy
Take 50% profit at $32.00; Stop loss at $24.00 if significant negative news or pipeline failures emerge.
Portfolio Allocation
2-4% for moderate risk tolerance (income/value focused), not suitable for aggressive growth portfolios.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is PFE Financially Healthy?
Valuation
P/E Ratio
19.55
Forward P/E
8.08
EV/EBITDA
7.06
Price/Book
1.54
Price/Sales
2.28
Profitability
Gross Margin
74.80%
Operating Margin
15.36%
Net Margin
11.83%
Return on Equity
8.37%
Revenue Growth
1.36%
EPS
$1.31
Balance Sheet
Current Ratio
1.16
Quick Ratio
0.87
Debt/Equity
0.75
Other
Beta (Volatility)
0.29
Dividend Yield
6.79%
Does PFE Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
Pfizer's wide moat is durable due to its vast portfolio of patented drugs, continuous investment in R&D to replenish its pipeline, and strong global distribution. While patent expirations are a continuous challenge, its scale and brand power allow it to absorb these impacts and innovate new solutions. The high regulatory hurdles and capital requirements for drug development also deter new entrants.
Moat Erosion Risks
- •Failure of the R&D pipeline to produce sufficient new blockbuster drugs to offset revenue loss from patent expirations (e.g., Ibrance, Eliquis).
- •Increased generic competition and biosimilar adoption eroding market share for established products at a faster rate than anticipated.
PFE Competitive Moat Analysis
Sign up to see competitive advantages
PFE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Retail sentiment likely mixed, with some attracted to dividend yield and stability, others wary of post-COVID revenue decline and lack of explosive growth.
Institutional Sentiment
Neutral. Q1 2026 beats likely prevented further downgrades, but no major upgrades or target increases were evident from the provided research, suggesting a 'hold' stance for most.
Insider Activity (Form 4)
No identifiable Form 4 transactions for named insiders (buys/sells) were available in the provided search results for the last 90 days. Therefore, no specific insider activity to report.
Options Flow
Normal options activity. No specific unusual put/call ratios or large block trades were indicated in the provided research to suggest strong directional institutional bets.
Earnings Intelligence
Next Earnings
2026-08-04
Surprise Probability
Medium
Historical Earnings Pattern
Historically, Pfizer tends to react modestly to earnings beats/misses, typically within a +/- 2-5% range, given its mature status. Significant movements are usually tied to major pipeline news or guidance changes.
Key Metrics to Watch
Competitive Position
Top Competitor
JNJ
Market Share Trend
Stable in core areas (e.g., vaccines, oncology, internal medicine) but facing competitive pressure and patent expirations. Gaining share in specific new product categories while losing on older ones.
Valuation vs Peers
Trading at a discount on forward P/E (approx. 9-11x vs. peer average of 12-15x) due to post-COVID revenue normalization and patent cliff concerns. This discount reflects lower growth expectations.
Competitive Advantages
- •Extensive R&D pipeline and global development capabilities across multiple therapeutic areas.
- •Global manufacturing and distribution network, ensuring broad market access.
- •Strong brand recognition and established relationships with healthcare providers and payers.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive PFE Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (August 4, 2026): Consensus EPS estimate of $0.68. A beat, especially driven by non-COVID product growth exceeding +7% YoY, could provide modest short-term uplift.
- •Update on Phase 3 Pipeline Assets (Q3 2026): Specific data readouts or regulatory filings for key oncology or immunology candidates could signal future revenue drivers, offsetting LOE concerns.
Medium-Term (6-18 months)
- •New Product Launches (FY2026-FY2027): Successful commercialization of recently approved or late-stage pipeline assets (e.g., in oncology, immunology, or rare diseases) reaching $500M+ annual revenue each by late FY2027.
- •Strategic Divestitures/Acquisitions (H2 2026-FY2027): Potential divestment of non-core assets to streamline operations or acquisition of bolt-on biotech firms with novel platforms to enhance future growth segments.
Long-Term (18+ months)
- •Biologics/Gene Therapy Platform Expansion (FY2028-FY2029): If Pfizer successfully builds out a leading biologics or gene therapy pipeline achieving 3+ blockbuster drug approvals ($1B+ annual sales each), it could re-rate long-term growth prospects.
- •Global Health Initiatives & Market Access (FY2028-FY2029): Deepened penetration into emerging markets or successful collaboration with global health organizations on major disease areas, expanding patient reach and market share in key geographies.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for PFE?
- ✓
Watch operational revenue growth of non-COVID products (should be >5% YoY).
- ✓
Monitor the success rate and commercial ramp-up of new product launches (e.g., tracking first-year sales for specific new drugs).
- ✓
Track progress of key Phase 3 clinical trials and regulatory approval timelines.
Bull Case Analysis
Sign up free to see the bull case
Competing with PFE
See how Pfizer Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Pfizer Inc Makes Money
Pfizer Inc. is a global pharmaceutical and biotechnology corporation that discovers, develops, manufactures, and sells medicines and vaccines for humans. It primarily generates revenue by selling patented prescription drugs across various therapeutic areas like oncology, inflammation & immunology, rare diseases, internal medicine, and vaccines to hospitals, pharmacies, governments, and patients worldwide. Its business model relies heavily on significant R&D investment to create innovative, patent-protected drugs, which are then globally marketed and sold, generating high margins until patent expiration allows for generic competition.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Pfizer Inc (PFE)?
As of June 5, 2026, Pfizer Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Pfizer Inc?
Pfizer Inc's market capitalization is approximately $146.4B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Pfizer Inc use?
PFE is the ticker symbol for Pfizer Inc. The company trades on the NYQ.
What is the risk level for PFE stock?
Our analysis rates Pfizer Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PFE?
Pfizer Inc currently has a price-to-earnings (P/E) ratio of 19.5. This is in line with broader market averages.
Does Pfizer Inc pay a dividend?
Yes, Pfizer Inc pays a dividend with a current yield of approximately 6.79%.
Is Pfizer Inc's revenue growing?
Pfizer Inc has reported revenue growth of 1.4%. The company is growing at a moderate pace.
Is PFE stock profitable?
Pfizer Inc has a profit margin of 11.8%. The company is profitable but margins are modest.
How often is the PFE DVR analysis updated?
Our AI-powered analysis of Pfizer Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 5, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PFE (Pfizer Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.